Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Iopamidol
Drug ID BADD_D01181
Description Iopamidol is a contrast agent developed by Bracco with nonionic, low-osmolar properties.
Indications and Usage Not Available
Marketing Status approved
ATC Code V08AB04
DrugBank ID DB08947
KEGG ID D01797
MeSH ID D007479
PubChem ID 65492
TTD Drug ID D0O2HQ
NDC Product Code 68225-077; 0270-1412; 68225-078; 68225-100; 0270-1315; 0270-1317; 0270-1411; 70436-126; 62331-006; 0270-1316; 68225-076; 0270-1314; 70436-124; 57876-222
UNII JR13W81H44
Synonyms Iopamidol | Jopamidol | Gastromiro | Iopamidol, (+-)-Isomer | Iopamidol, (R)-Isomer | Iopamidol, Sodium Salt, (S)-Isomer | Iopamiro | Isovue 370 | Niopam | Solutrast | Solutrast 370 | Solutrast Gastro | SQ 13,396 | B-15,000 | B 15,000 | B15,000 | B-15000 | B 15000 | B15000 | Isovue
Chemical Information
Molecular Formula C17H22I3N3O8
CAS Registry Number 60166-93-0
SMILES CC(C(=O)NC1=C(C(=C(C(=C1I)C(=O)NC(CO)CO)I)C(=O)NC(CO)CO)I)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Joint stiffness15.01.02.003---
Lacrimation disorder06.08.02.010---
Lacrimation increased06.08.02.0040.022763%
Laryngeal oedema10.01.05.003; 22.04.02.001; 23.04.01.005--
Lip swelling07.05.04.005; 10.01.05.005; 23.04.01.0070.034856%-
Loss of consciousness17.02.04.0040.054773%-
Malaise08.01.01.003--
Meningism17.02.05.007--
Meningitis aseptic11.01.03.002; 17.06.03.002---
Meningitis bacterial11.02.01.013; 17.06.10.002---
Menopausal symptoms21.02.02.002---
Muscle contractions involuntary15.05.03.008; 17.05.03.001---
Muscle spasms15.05.03.004--
Muscle spasticity15.05.04.011; 17.05.03.007--
Muscular weakness15.05.06.001; 17.05.03.0050.019206%
Musculoskeletal pain15.03.04.007--
Myalgia15.05.02.001--
Myelitis11.01.03.007; 17.06.02.001--
Myelitis transverse10.04.10.006; 17.06.02.002---
Myocardial infarction02.02.02.007; 24.04.04.009--
Myocardial ischaemia02.02.02.008; 24.04.04.010---
Nasal congestion22.04.04.0010.015649%
Nausea07.01.07.0010.142268%
Neck pain15.03.04.009--
Necrosis08.03.03.001; 24.04.02.006---
Nephropathy20.05.03.001---
Nephropathy toxic12.03.01.010; 20.05.03.0020.017783%-
Nephrotic syndrome20.05.01.002--
Neuropathy peripheral17.09.03.003---
Neurotoxicity12.03.01.011; 17.02.10.0020.039124%-
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 10 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene